CD47|Proteinase K|EGFR|BCMA|PD-L1|CD276|ACE2|TMPRSS2|Exosome Isolation Kits
Recombinant antibodies are monoclonal antibodies which are produced in vitro using synthetic genes. Different from regular monoclonal antibodies, recombinant antibodies are prepared without animals. Instead, they are produced by detecting the gene sequence of the antibody; and then the gene is inserted into a suitable cell line to produce the antibody. Because the antibodies are for sure, even if the original cell line dies or is mutated, the required cell line can be generated by gene insertion. That guarantees the high specificity and stability of recombinant antibodies. In addition, compared with regular antibodies, recombinant antibodies can offer a higher level of consistency between batches.
CUSABIO has been focused on the development and product of recombinant antibodies for more than 3 years. And there are 210 recombinant antibodies available now. Except for recombinant antibodies'own advantages, CUSABIO recombinant rabbit monoclonal antibodies are also known for higher purity and affinity, as well as the minimal deviation between batches. We can guarantee the quality for we produce and validate each of our antibodies in-house.
Here is the catalog of all recombinant antibodies. You can find the right ones for your research, or search them in the search box on the header part of this website.
If you can't find the antibody you need, please check CUSABIO recombinant antibody custom service.
Product Name |
Code |
Species Reactivity |
Application |
Size |
---|---|---|---|---|
SARS-CoV-2 Spike RBD Nanobody, HRP conjugated |
CSB-RA33245B2GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
SARS-CoV-2 Spike RBD Nanobody, FITC conjugated |
CSB-RA33245C2GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
SARS-CoV-2 Spike RBD Nanobody, Biotin conjugated |
CSB-RA33245D2GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
N Antibody |
CSB-RA33255A2GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, GICA | 100ul/50ul |
SARS-CoV-2 Spike RBD Nanobody |
CSB-RA33245A2GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, GICA, Neutralising | 100ul/50ul |
S Antibody, HRP conjugated |
CSB-RA33245B1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
S Antibody, FITC conjugated |
CSB-RA33245C1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
S Antibody, Biotin conjugated |
CSB-RA33245D1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
N Antibody, Biotin conjugated |
CSB-RA33255D1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
N Antibody, FITC conjugated |
CSB-RA33255C1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
N Antibody, HRP conjugated |
CSB-RA33255B1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA | 100ul/50ul |
S Antibody |
CSB-RA33245A1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, GICA, Neutralising | 100ul/50ul |
N Antibody |
CSB-RA33255A1GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, WB, GICA | 100ul/50ul |
N Antibody |
CSB-RA33255A0GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, GICA | 100ul/50ul |
S Antibody |
CSB-RA33245A0GMY | Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) | ELISA, GICA | 100ul/50ul |
FOXO3 Antibody |
CSB-RA008836A0HU | Human | ELISA, WB, IHC, IF | 100μl/50μl |
CDC45 Antibody |
CSB-RA005020A0HU | Human | ELISA | 100μl/50μl |
ATG12 Antibody |
CSB-RA002283A0HU | Human | ELISA | 100μl/50μl |
BAG3 Antibody |
CSB-RA002531A0HU | Human | ELISA, WB, IHC | 100μl/50μl |
FOS Antibody |
CSB-RA008790A0HU | Human, Mouse | ELISA, WB, IHC, IF, FC | 100μl/50μl |
NPPA Antibody |
CSB-RA016020A0HU | Human | ELISA | 100μl/50μl |
GCG Antibody |
CSB-RA009315A0HU | Human | ELISA | 100μl/50μl |
IGF2 Antibody |
CSB-RA011088A0HU | Human | ELISA | 100μl/50μl |
LTA Antibody |
CSB-RA013218A0HU | Human | ELISA | 100μl/50μl |
LMNA Antibody |
CSB-RA013003A0HU | Human | ELISA, IHC, IF, FC, IP | 100μl/50μl |
APOA2 Antibody |
CSB-RA001915A0HU | Human | ELISA, WB, IHC, FC | 100μl/50μl |
HSPB1 Antibody |
CSB-RA010833A0HU | Human | ELISA, WB, IHC, IF, FC, IP | 100μl/50μl |
ITGB1 Antibody |
CSB-RA011880A0HU | Human | ELISA, WB, IHC, IF, FC | 100μl/50μl |
GPX1 Antibody |
CSB-RA009866A0HU | Human | ELISA | 100μl/50μl |
HSP90AA1 Antibody |
CSB-RA011087A2HU | Human | ELISA, WB, IHC, IF | 100μl/50μl |
HSP90AA1 Antibody |
CSB-RA011087A1HU | Human | ELISA, IHC, IF | 100μl/50μl |
HSP90AA1 Antibody |
CSB-RA011087A0HU | Human, Rat | ELISA, WB, IHC, IF, IP | 100μl/50μl |
HSP90AA1/HSP90AB1 Antibody |
CSB-RA010802A0HU | Human, Rat | ELISA, WB, FC, IP | 100μl/50μl |
HNRNPC Antibody |
CSB-RA010605A0HU | Human | ELISA, WB, IHC, IF, FC, IP | 100μl/50μl |
CD63 Antibody |
CSB-RA004950A0HU | Human | ELISA, IHC, IF | 100μl/50μl |
RARA Antibody |
CSB-RA019338A0HU | Human | ELISA, IHC | 100μl/50μl |
PRKAR1A Antibody |
CSB-RA018694A0HU | Human | ELISA, WB, IF | 100μl/50μl |
HSPA8 Antibody |
CSB-RA010829A0HU | Human | ELISA, WB | 100μl/50μl |
CYP19A1 Antibody |
CSB-RA006394A0HU | Human | ELISA, WB, IHC, IF | 100μl/50μl |
CETP Antibody |
CSB-RA005267A0HU | Human | ELISA, IHC | 100μl/50μl |
SRC Antibody |
CSB-RA022650A0HU | Human, Mouse | ELISA, WB, IF, FC | 100μl/50μl |
MMP9 Antibody |
CSB-RA014679A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
FABP4 Antibody |
CSB-RA007945A0HU | Human | ELISA | 100μl/50μl |
ATF2 Antibody |
CSB-RA002270A0HU | Human | ELISA, WB, IHC | 100μl/50μl |
CD19 Antibody |
CSB-RA004888A0HU | Human | ELISA | 100μl/50μl |
IFNAR1 Antibody |
CSB-RA011046A0HU | Human | ELISA | 100μl/50μl |
ATF4 Antibody |
CSB-RA002272A0HU | Human | ELISA, WB, IHC, IF, FC, IP | 100μl/50μl |
VDAC1 Antibody |
CSB-RA025821A0HU | Human, Mouse, Rat | ELISA, WB, IHC | 100μl/50μl |
IL10 Antibody |
CSB-RA011580A0HU | Human | ELISA | 100μl/50μl |
YY1 Antibody |
CSB-RA026297A0HU | Human | ELISA | 100μl/50μl |
A stable and highly specific antibody plays an important role in obtaining real and repeatable experimental results. It is a big headache if the antibody used in the experiment does not work. And what's even worse is that you use the antibodies to repeat the same experiment but get inconsistent results.
It is estimated that the annual loss in research funding due to the use of antibodies without enough validation is about $ 800 million worldwide. At the same time, it has caused countless experimental failures, and a waste of precious samples and researchers'youth.
Nowadays, the antibody validations information provided by antibody manufacturers and academic articles is very helpful for you to select high-quality antibodies. However, there is still an inevitable problem: whether it is polyclonal antibodies extracted from animal serum or monoclonal antibodies produced by hybridomas, there are more or fewer differences between batches. And recombinant antibodies may finally solve this problem.
Recombinant antibodies refers to the application of molecular cloning and gene mutation technology to transform a gene coding sequence of an antibody to produce superior performance of antibodies, also known as genetically engineered antibodies. Comparing with monoclonal antibodies generated in vivo of living animals through hybridoma technology, recombinant antibodies are a type of monoclonal antibodies which are produced in vitro by using synthetic genes.
In recent years, the use of recombinant antibodies is becoming increasingly wider and deeper in both therapeutics and diagnostics. With significant advantages over conventional antibodies, recombinant antibodies become more and more favored. The most important point is that recombinant antibodies can maximize the humanization to solve the heterogeneity between different species.
Generally speaking, recombinant antibodies can be divided into three classes, including chimeric antibody, humanized antibody, fully humanized antibody and small molecular antibody.
Compared with traditional antibodies, recombinant antibodies have the advantages of being irresistible, which is one of the reasons for their gradually emerging. Here, we present the advantages one by one as follows:
Because recombinant antibodies have these unprecedented advantages, recombinant antibodies fulfill a large spectrum of functions spanning from research to diagnosis and treatment therapies for various diseases. Their specificity and low immunogenicity make them a great alternative to traditional forms of treatment, increasing the accuracy of targeting specific molecules and avoiding adverse side effects.
Additionally, for recombinant antibodies production, it follows principally similar workflow. Generally, it consists of five steps: the construction of antibody gene library, phage display, the separation of antibodies, the modification of the isolated antibodies, and the scaling up of the production of selected antibodies in the cell culture expression system.
Although the processes of recombinant antibodies production are same as workflow, we need to recognize that there are several obstacles to the production of recombinant antibodies, such as lower antibody production, and highly trained and experienced technicians. Due to the complexity and intensive high technology of recombinant antibody production, most scientists need to obtain them from outsourcing companies.
Read the article, The Overview of Recombinant Antibody, for more information.